A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin.

[1]  Y. Tabata,et al.  Preparation of stem cell aggregates with gelatin microspheres to enhance biological functions. , 2011, Acta biomaterialia.

[2]  V. Bergdall,et al.  Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. , 2011, The Journal of urology.

[3]  William R. Sones,et al.  Haemotoxicity of busulphan, doxorubicin, cisplatin and cyclophosphamide in the female BALB/c mouse using a brief regimen of drug administration , 2011, Cell Biology and Toxicology.

[4]  M. Pajic,et al.  Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo , 2010, Cell cycle.

[5]  D. Salomon,et al.  Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. , 2010, International journal of pharmaceutics.

[6]  S. Howell,et al.  CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. , 2010, Molecular pharmaceutics.

[7]  Yasuhiko Tabata,et al.  Controlled Release of Stromal-Cell-Derived Factor-1 from Gelatin Hydrogels Enhances Angiogenesis , 2010, Journal of biomaterials science. Polymer edition.

[8]  Y. Tabata,et al.  In Vitro Proliferation and Chondrogenic Differentiation of Rat Bone Marrow Stem Cells Cultured with Gelatin Hydrogel Microspheres for TGF-β1 Release , 2010, Journal of biomaterials science. Polymer edition.

[9]  A. Stojadinovic,et al.  Evidence‐based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future , 2009, Journal of surgical oncology.

[10]  N. Nitta,et al.  An initial clinical study on the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors. , 2009, European journal of radiology.

[11]  Y. Tabata,et al.  Effect of gelatin hydrogel incorporating fibroblast growth factor 2 on human meniscal cells in an organ culture model. , 2009, The Knee.

[12]  Antonios G Mikos,et al.  Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2. , 2008, Acta biomaterialia.

[13]  Y. Tabata,et al.  Promotion of bone regeneration by CCN2 incorporated into gelatin hydrogel , 2008 .

[14]  Y. Tabata,et al.  Controlled release systems of angiogenic growth factors for cardiovascular diseases , 2007, Expert opinion on drug delivery.

[15]  K. Yasuda,et al.  In situ regeneration of adipose tissue in rat fat pad by combining a collagen scaffold with gelatin microspheres containing basic fibroblast growth factor. , 2006, Tissue engineering.

[16]  R. Hariprasad,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[17]  Y. Tabata,et al.  Controlled release of plasmid DNA from hydrogels prepared from gelatin cationized by different amine compounds. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[18]  R. Burger,et al.  Use of a dummy (pacifier) during sleep and risk of sudden infant death syndrome (SIDS): population based case-control study , 2005, BMJ : British Medical Journal.

[19]  Y. Tabata,et al.  Regeneration of Canine Tracheal Cartilage by Slow Release of Basic Fibroblast Growth Factor from Gelatin Sponge , 2006, ASAIO journal.

[20]  Yasuhiko Tabata,et al.  Osteogenic differentiation of mesenchymal stem cells in biodegradable sponges composed of gelatin and beta-tricalcium phosphate. , 2005, Biomaterials.

[21]  Y. Tabata,et al.  In vivo degradability of hydrogels prepared from different gelatins by various cross-linking methods , 2005, Journal of biomaterials science. Polymer edition.

[22]  Ze Lu,et al.  Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy , 2004, Clinical Cancer Research.

[23]  Yoshiaki Hirano,et al.  Effect of culture substrates and fibroblast growth factor addition on the proliferation and differentiation of rat bone marrow stromal cells. , 2004, Tissue engineering.

[24]  Tatsuo Nakamura,et al.  Slow release of bone morphogenetic protein 2 from a gelatin sponge to promote regeneration of tracheal cartilage in a canine model. , 2004, The Journal of thoracic and cardiovascular surgery.

[25]  Y. Tabata,et al.  In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[26]  M. Gore,et al.  Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. , 2002, The Lancet. Oncology.

[27]  S. Hundahl.  Surgical quality in trials of adjuvant cancer therapy , 2002, Journal of surgical oncology.

[28]  T. Imai,et al.  Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C. , 2002, International journal of pharmaceutics.

[29]  N. Nishiyama,et al.  Cisplatin‐incorporated Polymeric Micelles Eliminate Nephrotoxicity, While Maintaining Antitumor Activity , 2001, Japanese journal of cancer research : Gann.

[30]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[31]  S. Fukushima,et al.  Antitumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo. , 1999, Cancer research.

[32]  Y. Ikada,et al.  Biodegradation of hydrogel carrier incorporating fibroblast growth factor. , 1999, Tissue engineering.

[33]  D. M. Brown,et al.  Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  T. Tani,et al.  Antitumor effect of cisplatin incorporated into polylactic acid microcapsules. , 1999, Artificial organs.

[35]  S. Natsugoe,et al.  Design and testing of a new cisplatin form using a base material by combining poly‐D,L‐lactic acid and polyethylene glycol acid against peritoneal metastasis , 1998, International journal of cancer.

[36]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[37]  Y. Ikada,et al.  In vivo suppressive effects of copoly(glycolic/L-lactic acid) microspheres containing CDDP on murine tumor cells , 1996 .

[38]  T. Kubota,et al.  Antitumor activity of cis‐diamminedichloroplatinum II against human tumor xenografts depends on its area under the curve in nude mice , 1996, Journal of surgical oncology.

[39]  A. Hagiwara,et al.  Prophylaxis and treatment of peritoneal carcinomatosis: Intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles , 1995, World Journal of Surgery.

[40]  Y. Otani,et al.  Gene expression of interstitial collagenase (matrix metalloproteinase 1) in gastrointestinal tract cancers , 1994, Journal of Gastroenterology.

[41]  M. Wilchek,et al.  Cis-platinum (II) complexes of carboxymethyl-dextran as potential antitumor agents. II. In vitro and in vivo activity. , 1986, Cancer biochemistry biophysics.

[42]  Y. Tabata,et al.  Promotion of bone regeneration by CCN2 incorporated into gelatin hydrogel. , 2008, Tissue engineering. Part A.

[43]  T. Taguchi,et al.  A standardized method of using nude mice for the in vivo screening of antitumor drugs for human tumors , 2004, Surgery Today.

[44]  M. Shirasu,et al.  Micrometastasis in Omental Milky Spots and Intraperitoneal Chemotherapy with Carbon-adsorbed Mitomycin C (MMC-CH) Against Peritoneal Cancer Dissemination in Gastric Cancer. , 1994 .